Literature DB >> 26477723

Prognostic marker of nonfatal pulmonary thromboembolism: decreased glomerular filtration rate or increased age?

Serkan Duyuler1, Pınar Türker Bayır.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26477723      PMCID: PMC5336975          DOI: 10.5152/AnatolJCardiol.2015.6413

Source DB:  PubMed          Journal:  Anatol J Cardiol        ISSN: 2149-2263            Impact factor:   1.596


× No keyword cloud information.
To the Editor, We read the article titled “Chronic kidney disease: Prognostic marker of nonfatal pulmonary thromboembolism” by Ouatu et al. (1) published in Anatol J Cardiol 2014 Dec 31 with great interest. In this article, the authors aimed to elucidate the relationship between venous thromboembolism-related mortality and renal dysfunction assessed by a regression-based MDRD formula. As a result of their investigation, the authors proposed that GFR is an independent predictor of 2-year mortality in pulmonary embolism besides troponin, dyslipidemia, acceleration time of pulmonary ejection, pericardial effusion, and BNP Chronic kidney disease is a well-known prognostic factor, indicating increased morbidity and mortality in various cardiovascular diseases and acute pulmonary embolism. Impairment of renal functions may be related to preexisting chronic kidney disease or deteriorations secondary to hemodynamic failure (2). In clinical practice, renal functions are usually evaluated using creatinine-based formulae, which are based on age and gender. This situation may cause biases even after adjustment for age and gender in statistical analysis when evaluating the data for independence. It may not be cost-effective to evaluate renal functions with inulin or radioisotope-based quantitative determinants of GFR other than regression-based GFR formulae in a relatively large number of cases. According to the current guidelines (3), various prediction rules have been proposed for the prognostic assessment of patients with acute pulmonary embolism, and the pulmonary embolism severity index is one of the most widely used scores. This scoring system and its simplified form are composed of several variables including “age.” Male gender is also a poor prognosis predictor in the original form of the scoring system. In the current article by Ouatu et al. (1), gender difference was not significant between survivors and non-survivors, while age was significantly higher in non-survivors. We wonder if the authors adjusted their findings for age and possibly for gender or if they brought these variables into regression models. Otherwise, it is hard to propose GFR as an independent predictor of mortality owing to the highly possible collinearity between age and GFR. These concerns could be kept in mind while evaluating the results of this study. Author’s Reply Authors of this mentioned article did not send any reply for this Letter to Editor, in spite of our insistently request.
  3 in total

1.  Renal biomarkers and prognosis in acute pulmonary embolism.

Authors:  Thomas M Berghaus; Martin Schwaiblmair; Wolfgang von Scheidt
Journal:  Heart       Date:  2012-08       Impact factor: 5.994

2.  2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.

Authors:  Stavros V Konstantinides; Adam Torbicki; Giancarlo Agnelli; Nicolas Danchin; David Fitzmaurice; Nazzareno Galiè; J Simon R Gibbs; Menno V Huisman; Marc Humbert; Nils Kucher; Irene Lang; Mareike Lankeit; John Lekakis; Christoph Maack; Eckhard Mayer; Nicolas Meneveau; Arnaud Perrier; Piotr Pruszczyk; Lars H Rasmussen; Thomas H Schindler; Pavel Svitil; Anton Vonk Noordegraaf; Jose Luis Zamorano; Maurizio Zompatori
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

3.  Chronic kidney disease: Prognostic marker of nonfatal pulmonary thromboembolism.

Authors:  Anca Ouatu; Daniela Maria Tãnase; Mariana Floria; Simona Daniela Ionescu; Valentin Ambãruş; Cãtãlina Arsenescu-Georgescu
Journal:  Anatol J Cardiol       Date:  2014-12-31       Impact factor: 1.596

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.